Random SARS-CoV-2 antibody screening in Egypt during the COVID-19 third wave
Gaafar, M., balah, M., Kassem, H., Sabry, H., ElMessiery, R., Soliman, N. (2023). Random SARS-CoV-2 antibody screening in Egypt during the COVID-19 third wave. EKB Journal Management System, 32(2), 79-87. doi: 10.21608/ejmm.2023.291146
Maha Mohammed Gaafar; Mariam Mahmoud balah; Hebatallah Kassem; Hend Aly Sabry; Reem ElMessiery; Noha Salah Soliman. "Random SARS-CoV-2 antibody screening in Egypt during the COVID-19 third wave". EKB Journal Management System, 32, 2, 2023, 79-87. doi: 10.21608/ejmm.2023.291146
Gaafar, M., balah, M., Kassem, H., Sabry, H., ElMessiery, R., Soliman, N. (2023). 'Random SARS-CoV-2 antibody screening in Egypt during the COVID-19 third wave', EKB Journal Management System, 32(2), pp. 79-87. doi: 10.21608/ejmm.2023.291146
Gaafar, M., balah, M., Kassem, H., Sabry, H., ElMessiery, R., Soliman, N. Random SARS-CoV-2 antibody screening in Egypt during the COVID-19 third wave. EKB Journal Management System, 2023; 32(2): 79-87. doi: 10.21608/ejmm.2023.291146

Random SARS-CoV-2 antibody screening in Egypt during the COVID-19 third wave

Egyptian Journal of Medical Microbiology
Volume 32, Issue 2, April 2023, Page 79-87  XML PDF (391.74 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2023.291146
View on SCiNiTO View on SCiNiTO
Authors
Maha Mohammed Gaafar1; Mariam Mahmoud balah2; Hebatallah Kassem3; Hend Aly Sabry4; Reem ElMessiery5; Noha Salah Soliman email 2
11Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Egypt
2Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Egypt
3Department of Clinical and Chemical pathology, Kasr-Alainy Center of Clinical Oncology and Nuclear Medicine, School of Medicine, Cairo University
4Department of Public Health & Community Medicine, Kasr Al-Ainy School of Medicine
54Department of Internal Medicine, Faculty of Medicine, Cairo University, Egypt
Abstract
Background: Since its first hit in 2019, COVID-19 pandemic has caused devastating consequences all over the globe. Serological testing can assess the level of humoral immune response and can guide for appropriate health decisions. Objective: This work aimed to test performance agreement between rapid tests and ELISA in serological detection of COVID-19 antibodies among generally randomized Egyptian participants. Methodology: Total 238 randomized Egyptian participants were serologically screened for SARS-CoV-2 IgM and IgG using COVID-19 IgM/IgG Combo rapid test and NovaLisa SARS-CoV-2 IgM and IgG ELISA kit in the period from March 2021 to June 2021 (pandemic third wave). Result: COVID-19 antibodies showed seroprevalence rate of 47.47%, distributed among symptomatic and asymptomatic individuals by rates of 51% and 42.5%, respectively. IgM and IgG antibodies had rates of 8.8% and 35.6%, while rates of 10.9% and 28.2% by ELISA respectively. The agreement between ELISA and rapid test was none to slight for IgM (p = 0.35), while fair for IgG; (p < 0.001). Conclusion: COVID-19 antibodies were positive in nearly half of enrolled participants. Rapid test showed fair agreement for IgG, while none to slight agreement for IgM with ELISA, thus can not replace ELISA in serological testing.
Keywords
COVID-19 antibodies; Serological diagnosis; SARS-CoV-2
Statistics
Article View: 97
PDF Download: 88